In a significant boost for India's medical manufacturing sector, Lord's Mark Industries Ltd has achieved a major regulatory milestone. The diversified conglomerate has successfully secured US Food and Drug Administration (FDA) registrations for a portfolio of 153 orthosurgical products. This achievement sets a new benchmark for Indian medical device manufacturers aiming for global markets.
A Manufacturing Ecosystem Built for Global Standards
The entire range of FDA-listed products is manufactured at the company's facility in Silvassa. This plant is designed as a globally aligned manufacturing ecosystem, rigorously built to meet international regulatory standards. The operation runs on benchmarked production protocols, supported by robust quality management systems and validated processes.
End-to-end traceability and a stringent compliance framework are integral to the facility's operations, ensuring it consistently meets the exacting requirements of the US FDA. This infrastructure underscores the company's commitment to creating export-ready, world-class medical manufacturing capabilities within India.
Diverse Portfolio Gains Regulatory Recognition
The US FDA-listed portfolio showcases the depth and diversity of Lord's Mark's manufacturing prowess. It encompasses a wide array of orthopaedic and surgical support products essential for patient care and rehabilitation. Key products in the registered list include:
- Orthopaedic braces and spinal supports
- Lord’s Activeguard knee and ankle braces
- Compression stockings and hernia belts
- Soft and hard cervical collars
- Post-surgical rehabilitation products
- Disinfectant wipes and adhesive bandages
This broad spectrum highlights the company's comprehensive approach to orthopaedic care solutions.
Positioning India as a Global Medtech Hub
Commenting on this landmark achievement, Sachidanand Upadhyay, Managing Director of Lord's Mark Industries Ltd, emphasized its broader significance. He stated that the milestone "reinforces our belief that world-class medical devices can be designed, manufactured, and regulated from India at a global scale."
Upadhyay added that the recognition for 153 products reflects the strength of the Silvassa manufacturing platform and the company's regulatory discipline. The long-term vision, he noted, is to firmly position India as a trusted and reliable source for high-quality, globally compliant healthcare solutions.
Expanding International Market Access
This regulatory accomplishment significantly strengthens Lord's Mark Industries' ability to access stringent international markets. The company is now poised to expand its reach in key regions including the United States, Latin America, and the Middle East.
As healthcare systems worldwide increasingly seek cost-effective yet regulation-compliant orthopaedic products, Lord's Mark is strategically positioned to grow its institutional supplies, hospital partnerships, and distributor-led exports. This move is facilitated through its US-based subsidiary, Lord’s Mark Global LLC.
With this development, Lord's Mark Industries joins an elite group of Indian healthcare manufacturers with established US FDA recognition. This not only marks a corporate triumph but also contributes meaningfully to India's growing footprint in the global medical technology value chain, showcasing the 'Make in India' initiative's potential in high-stakes, quality-critical sectors.
